Pharma Lab news
Funding & Finance
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Eli Lilly and Company and Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other...
Drug Discovery & Development
European Commission approves Kygevvi (doxecitine and doxribtimine) as first and only treatment for thymidine kinase 2 deficiency
UCB, a global biopharmaceutical company, has announced that the European Commission (EC) has granted marketing authorisation under exceptional circumstances for Kygevvi (doxecitine and doxribtimine)...
Drug Discovery & Development
Eisai and Nuvation Bio announce marketing authorisation application for taletrectinib for the treatment of advanced ROS1-positive non-small cell lung cancer validated by the European...
Eisai Co, a human-centred global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio, a global oncology company...
Funding & Finance
Ellison purchase swells triangle’s lab space
Oxfordshire, a key part of UK life sciences’ Golden Triangle region, had an annual take-up of lab space last year amounting to 620,200 sq...
Events and Conferences
Cambridge’s grassroots life sciences showcase branches out to Oxford and London
Cambridge Wide Open Week (CWOW) returns 11–19 June 2026, sharing the spirit and buzz of the week-long, interactive festival with Oxford and London for...
Drug Discovery & Development
Zegfrovy (Sunvozertinib) shows profound antitumor activity as first-line treatment in advanced NSCLC patients with PACC or other uncommon mutations
Dizal, a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, has announced the presentation of new clinical data for Zegfrovy® (sunvozertinib)...
Clinical Trials Insights
Ebglyss (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
New long-term data shows Eli Lilly and Company's Ebglyss (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with...
Clinical Trials Insights
Bimzelx (bimekizumab-bkzx) data shows durable symptom control throughout three years in hidradenitis suppurativa
UCB, a global biopharmaceutical company, announced data for Bimzelx in active moderate-to-severe hidradenitis suppurativa (HS) at the 2026 American Academy of Dermatology (AAD) Annual...
- Advertisement -
- Advertisement -
Latest stories
© 2026 Pharma Press Publishing.